

Anti-PD-1 (Camrelizumab) humanized Antibody

05/20

CATALOG NO.: A2132-100 (100 µg)

BACKGROUND DESCRIPTION: Camrelizumab (AiRuiKa™) is a humanized monoclonal IgG4 anti-PD-1 monoclonal antibody developed by Jiangsu Hengrui Medicine Co. Ltd for the treatment of various solid and hematological malignancies. Upon administration, the antibody blocks the binding of PD-1 to its ligands PD-L1 and PD-L2. This inhibits PD-1 downstream signaling and restores normal immune function by activating cytotoxic T lymphocytes and T cell-mediated immune responses against cancer cells. Currently, Camrelizumab is being investigated for treatment of advanced hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC) and Hodgkin lymphoma

ALTERNATE NAMES: PDCD1, PD1, CD279, SLEB2, hPD-1, hPD-I, AiRuiKa™, SHR-1210, HR 301210, INCSHR 1210

ANTIBODY TYPE: Monoclonal

HOST/ISOTYPE: CHO cells / Human IgG4

IMMUNOGEN: Camrelizumab

FORM: Liquid

FORMULATION: In PBS, pH 7.2

STORAGE CONDITIONS: Undiluted antibody solution should be stored at 4°C in the dark and avoid freezing the solution.

APPLICATIONS AND USAGE: In vivo studies

This information is only intended as a guide. The optimal dilutions must be determined by the user

RELATED PRODUCTS:

Anti-PD-1 (Pembrolizumab), Humanized Antibody (A1306)
 Anti-PD-1 (CD279), Rabbit Monoclonal Antibody (A1825)
 Anti-PD-L1 (Durvalumab), Human IgG1 Antibody (A2109)
 Anti-PD-1 Biotinylated Antibody (A1996)
 Anti-PD-L1 (Atezolizumab), Humanized Antibody (A1305)

FOR RESEARCH USE ONLY! Not to be used on humans.